Clene Shares Fall Despite Multiple Sclerosis Candidate Showing Neurological Improvements

Clene Inc CLNN has announced topline results from the Phase 2 VISIONARY-MS trial of CNM-Au, an investigational gold nanocrystal suspension, in stable relapsing-remitting multiple sclerosis.
As announced in February, the trial was stopped prematurely due to COVID-19 pandemic operational challenges, limiting enrollment to 73 out of the 150 planned participants.
CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity and modified Multiple Sclerosis Functional Composite compared to placebo over 48 weeks in the mITT population.
Also Read: Clene's CNM-Au8 Shows Decreased Mortality Amyotrophic Lateral Sclerosis Patients.
Consistent improvements favoring CNM-Au8 were seen across paraclinical biomarkers.
CNM-Au8 treatment was well-tolerated, and there were no significant safety findings reported.
Rob Etherington, CEO & president, added, "we also await additional evidence of clinical efficacy from the HEALEY ALS Platform Trial, which is expected to report topline data later this quarter."
Clene ended Q2 with cash, cash equivalents, and marketable investment securities of $26.3 million and entered into a $3.0 million loan facility to support the development of a commercial manufacturing facility.
Price Action: CLNN shares are down 8.41% at $3.16 during the premarket session on the last check Monday.

Earnings Calendar